C. Allen

Abstract 4076: A novel prodrug of indoximod with enhanced pharmacokinetic properties

C. Link, Sanjeev Kumar, E. Brincks, 2017 .

Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy.

Charles J. Link, James Adams, D. Munn, 2013 .

Indoximod opposes the immunosuppressive effects mediated by IDO and TDO via modulation of AhR function and activation of mTORC1

Lifu Wang, C. Link, Sanjeev Kumar, 2020, Oncotarget.

Abstract 5023: Synergistic antitumor effects of combinatorial immune checkpoint inhibition with anti-PD-1/PD-L antibodies and the IDO pathway inhibitors NLG-919 and indoximod in the context of active immunotherapy

D. Munn, C. Link, Madhav Sharma, 2014 .